Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 199 of the 202 references it cites were found in a registry or an index.

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Open access
Golde, Todd E. · 2022 · Neurotherapeutics

Abstract

Scientific advances over the last four decades have steadily infused the Alzheimer's disease (AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune activation states in the brain would provide disease modification. Unfortunately, this optimistic scenario has not yet played out. Though a recent approval of the anti-Aβ aggregate binding antibody, Aduhelm (aducanumab), as a "disease-modifying therapy for AD" is viewed by some as a breakthrough, many remain unconvinced by the data underlying this approval. Collectively, we have not succeeded in changing AD from a largely untreatable, inevitable, and incurable disease to a treatable, preventable, and curable one. Here, I will review the major foci of the AD "disease-modifying" therapeutic pipeline and some of the "open questions" that remain in terms of these therapeutic approaches. I will conclude the review by discussing how we, as a field, might adjust our approach, learning from our past failures to ensure future success.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13311-022-01201-2

Cites

199 of 199 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 202 references

Research works printed but not linked: 2

  1. Black, 2006, Efficacy and safety ofMPC-7869 (R-flurbiprofen), a selective Abeta42 loering agent in mild Alzheimer's disease: results of a 12-month phase 2 trial and 1-year follow on study, Neurology, 66, A347
  2. Golde, 2010, Targeting Aβ and tau in Alzheimer's disease, an early interim report, Exp Neurol, 223, 252, 10.1016/j.expneurol.2009.07.035 · DOI · Paper page

Cited by

See all 124

Metadata

Authors
Golde, T. E.
Affiliations
University of Florida (US)
Corresponding author
Golde, Todd E.
Venue
Neurotherapeutics
Publisher
Elsevier BV
Published
2022-01
Volume
19
Issue
1
Pages
209-227
ISSN
1878-7479 (ISSN-L)
OpenAlex
W4214774022
Cited by
119
References
202
Citations by year
2026: 11 · 2025: 38 · 2024: 39 · 2023: 25 · 2022: 6
FWCI
3.75
Type
journal article
Language
en
Open access
Licence
Locations
  • Neurotherapeutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (P30AG066506)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, disease-modifying therapy, amyloid-beta, tau protein, innate immune activation, aducanumab, anti-amyloid antibodies, clinical trial failure, drug development strategy
MeSH terms
Alzheimer Disease, Brain, Humans, Immunotherapy, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers. https://app.cochat.ai/papers/10.1007/s13311-022-01201-2
The paper
Golde, T. E. (2022). Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers. Neurotherapeutics. https://doi.org/10.1007/s13311-022-01201-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.